Addiction one of the Largest growing Problem’s in the world today. This Press Release Service will bring you the newest services and research available.
[ad_1]
Pharmacy Purchasing & Products Report Identified EQUASHIELD as Top Choice for Administration and Preparation PORT WASHINGTON, N.Y., Sept. 8, 2023 /PRNewswire/ — EQUASHIELD, a pioneer in closed system transfer devices (CSTDs) and automated pharmacy compounding solutions, is thrilled to…
[ad_2]
[ad_1]
BERLIJN, 9 september 2023 /PRNewswire/ — Target Global Acquisition I Corp. (Nasdaq: TGAA) (het “bedrijf”) heeft vandaag aangekondigd dat zijn raad van bestuur (de “raad”), op verzoek van Target Global Sponsor Ltd (de “sponsor”), heeft besloten om de datum te verlengen tegen dewelke het…
[ad_2]
[ad_1]
In addition, the Society, along with other patient advocacy groups, helped found and launch Project Mercury, a global collaboration platform to address clinical trial readiness and patient access around the world. Fulcrum is a sustaining industry member of Project Mercury. Project Mercury is key to both the Society and Fulcrum’s ongoing work together. Mel Hayes, Chief Operations Officer of Fulcrum, commented on the FSHD Society’s contribution to the REACH trial: “As the global sustaining member of Project Mercury and a longtime collaborator with the FSHD Society, Fulcrum is excited to announce that we have reached a major milestone with completion of enrollment in the REACH Phase III clinical trial. This REACH milestone, coupled with Project Mercury’s global task force ambitions and the Society’s work to prepare the FSHD community for its potential first therapy for FSHD serves as an inflection point for the FSHD community.”
Fulcrum Therapeutics has successfully enrolled 260 patients in the REACH Phase 3 trial across nine countries in the United States, Canada, and Europe. The trial employs a rigorous, double-blind, placebo-controlled design to evaluate the efficacy and safety of losmapimod for FSHD treatment. Patients were randomized 1:1 to receive either losmapimod, administered orally as a 15 mg tablet twice a day, or a placebo. Over a 48-week treatment period, various endpoints, including Reachable Workspace (RWS), muscle fat infiltration (MFI), Patient Global Impression of Change (PGIC), and Quality of Life in Neurological Disorders of the Upper Extremity (Neuro QoL UE), will be assessed. Moreover, REACH encompasses patient-centered evaluations of healthcare utilization.
Topline data from the Phase 3 REACH trial is anticipated to be reported in Q4 of 2024, bringing the FSHD community one step closer to the potential approval of the first-ever therapy for this challenging condition. Read the full press release from Fulcrum Therapeutics here.
Mark Stone, CEO of the FSHD Society, conveyed his excitement about the importance of this news for the FSHD community by stating, “This represents reaching a significant milestone and is a major step forward to providing safe and effective treatments for everyone living with FSHD! We are proud of our partnership with Fulcrum and the impact they are having on drug development in FSHD.”
About the FSHD Society
The FSHD Society is the world’s largest research-focused patient advocacy organization for facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent forms of MD. Over the past 32 years, the organization has catalyzed major advancements and worked to accelerate the development of treatments and a cure to end the pain, disability, and suffering endured by one million people worldwide who live with FSHD. The FSHD Society has transformed the landscape for FSHD research and is committed to making sure that no one faces this disease alone.
The Society offers a community of support, news, and information through its website at https://www.fshsociety.org.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, formerly FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com.
About Project Mercury
Project Mercury is an open collaboration among stakeholders from across the globe coming together to overcome the challenges that could slow or prevent effective FSHD therapies from getting to patients everywhere. This collaboration takes place at the global level through a Global Task Force and at the local level, through Country Working Groups. The Task Force and the Working Groups are all led by patient advocacy organizations of the World FSHD Alliance. This global-local approach ensures customization of Project Mercury’s work at the local level while sharing resources at the global level. More information about Project Mercury can be found at https://www.projectmercuryfshd.org.
Media Contact
June Kinoshita, FSHD Society, 781-301-6649, [email protected], https://www.fshdsociety.org
SOURCE FSHD Society
[ad_2]
[ad_1]
CAIRO, Sept. 8, 2023 /PRNewswire/ — The European Parliamentary Forum for Sexual and Reproductive Rights (EPF) today showcased the inaugural Middle East & North Africa Contraception Policy Atlas in Cairo. Findings from this unparalleled advocacy and policy tool, which provides essential…
[ad_2]
[ad_1]
AUSTIN, Sept. 7, 2023 /PRNewswire/ — Fagron Sterile Services US (FSS), a prominent 503B Outsourcing Facility, is proud to announce their selection as a recipient of a 2023 Project PROTECT grant awarded by Angels for Change. This accolade recognizes FSS as a dedicated Protector of…
[ad_2]
[ad_1]
NORTH BETHESDA, Md., Sept. 7, 2023 /PRNewswire-PRWeb/ — The International Society for Pharmaceutical Engineering (ISPE) is pleased to announce the results of our 2023–2024 International Board of Directors election. The election was run by an independent third party, Intelliscan, Inc., which provided ISPE with the final audited results.
The Board is responsible for the governance and strategic direction of the Society and will assume their elected positions at the 2023 ISPE Annual Meeting & Expo, taking place in Las Vegas, NV, USA, and virtually from 15–18 October. The following pharmaceutical industry leaders have been elected to positions on the 2023–2024 ISPE International Board of Directors.
Officers:
Directors Elected to a Second Term:
New Director:
Continuing Board Members:
The following Directors were elected in 2022 to serve a two-year term and will continue their service on the Board.
Emerging Leader Representative, Ex Officio:
Board Members Completing Service:
The following individuals will complete their Board service and end their term at the 2023 ISPE Annual Meeting & Expo. ISPE thanks these individuals for their dedication and commitment to the organization.
Visit ISPE Board of Directors Election Results and delve into comprehensive biographies of all the esteemed members of the ISPE’s International Board of Directors.
About ISPE
The International Society for Pharmaceutical Engineering (ISPE) is a global nonprofit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 20,000+ members of ISPE provide solutions to complex pharmaceutical industry challenges through innovation, member and workforce development, and technical, regulatory, and compliance collaborations in more than 120 countries worldwide. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland, USA, and its operations center in Tampa, Florida, USA. For more information, visit ISPE.org.
Media Contact
Brad Ettinger, VP Marketing & Communications, ISPE, 3013649203, [email protected], www.ispe.org
SOURCE ISPE
[ad_2]
[ad_1]
Said Dave Boozer (Administrator, Standifer) about their commitment to delivering quality care to its residents, “At the Health Center at Standifer Place, we don’t want to just settle for good. We are committed to being the leader in customer satisfaction and the provider of choice in our community. Our Enhanced Respiratory Care Accreditation demonstrates our continuing mission to deliver optimal care to the Chattanooga community.”
Cyndi Finley, RRT (Respiratory Director, Standifer) commented on prolonged mechanical ventilation, “Prolonged Mechanical Ventilation is a patient safety issue that significantly impacts the quality of life. Patients requiring mechanical ventilation need enhanced respiratory care to ensure they are not only receiving quality care but have the best opportunity to be liberated from being on a ventilator.”
Michael Wong, JD (Executive Director, Physician-Patient Alliance for Health & Safety) emphasized the patient safety and quality of care that the Chattanooga community will now enjoy, saying, “When families send their loved ones and friends to a healthcare facility, they want to make sure that they are receiving the best care possible. For the Chattanooga community, the Health Center at Standifer Place is such a facility.”
Gene Gantt, RRT, FAARC (Former Chair AARC Long Term Care; AARC Representative to the Respiratory Compromise Institute; President, Eventa, LLC) reflected on his long-term relationship with The Health Center at Standifer Place. “Standifer Place was the very first Enhanced Respiratory Care unit in Tennessee, opening in 2001, so I have known Dave and Cyndi for many years and I am pleased that the Health Center at Standifer Place is the second facility in the United States to receive Enhanced Respiratory Care Accreditation. The team at Standifer Place is committed to delivering quality care to its patients.” Mr. Gantt is also a member of PPAHS’s board of advisors.
The Enhanced Respiratory Care Standards of Care are supported and endorsed by the American Association for Respiratory Care. Carl Hinkson, MS, RRT-NPS, ACCS, FAARC (President, American Association for Respiratory Care) writes:
“The American Association for Respiratory Care (AARC) would like to express our support and endorsement of your efforts in developing standards of care and facility accreditation for long-term mechanical ventilation in skilled nursing facilities. As the leading professional association for respiratory therapists in the United States, we recognize the importance of ensuring patients receive the highest quality care possible.”
Mr. Gantt, whose team has developed and managed the Enhanced Respiratory Care program in Tennessee since 2013, said, “The Enhanced Respiratory Care Program is based on standards published by the American Association for Respiratory Care. Utilized in Tennessee, this Program has achieved liberation rates of 65% and has earned national recognition of excellence from the American College of Chest Physicians.”
For more on the Enhanced Respiratory Care Accreditation and how to apply for accreditation, please visit https://ppahs.org/accreditation-of-facilities/
About Health Center at Standifer Place
The Health Center at Standifer Place (HCSP) is located on a beautiful 44 acre campus near Hamilton Place Mall in scenic Chattanooga, Tennessee. On our property are Skilled Nursing facilities, an Assisted Living Facility, Adult Day Care Services and an Independent Living Facility. We also offer Assistive Home Services in the Community. Our Licensed Physicians, Respiratory Therapists and Nurse Practitioners offer services including: Alzheimer’s and memory care in a secured environment, on-site professional medical services, fall and wound prevention programs, therapeutic recreation, and respiratory therapy. The rehabilitation department provides physical, occupational and speech therapy. For more information, please visit https://standiferplace.org/.
About Physician-Patient Alliance for Health and Safety
Physician-Patient Alliance for Health & Safety is ranked internationally as a top-100 patient safety organization (Agilience Authority Index, June 2023) and is a national advocacy force for addressing patient health and safety priorities shared by patients, physicians, regulators, and industry. PPAHS seeks to ensure that the best medications, medical inventions, and technology that can improve care and reduce costs are employed. PPAHS works to advance patient health and safety by developing and highlighting best practices and recommendations through better use and application of clinical practices and experiences, information technologies and checklists, and healthcare information. As a voice in support of ideas and innovation that can improve care, we encourage a health ecosystem that fosters a culture of patient safety. For more about PPAHS, please go to www.ppahs.org.
Media Contact
Michael Wong, PHYSICIAN-PATIENT ALLIANCE FOR HEALTH & SAFETY, 1 8477705582, [email protected], https://ppahs.org/
SOURCE PHYSICIAN-PATIENT ALLIANCE FOR HEALTH & SAFETY
[ad_2]
[ad_1]
“Although mental health and medical conditions can be equally congruent, insurers and employers typically only focus on the primary diagnosis when determining the time away from work,” said Ms. Bloom-Pugliese. “What’s missing is the analysis and understanding of the broader impact of mental health conditions as co-morbidities for physical diagnoses. We look forward to sharing recommendations for how workers’ compensation professionals can better manage these claims moving forward.”
For those interested in attending National Comp, registration details and additional information can be found at: https://wcconference.com/.
About ODG
ODG, an MCG Health company, (http://www.mcg.com/odg) provides unbiased, evidence-based guidelines that support workers’ comp, disability, and auto liability claims and medical management in their efforts to confidently and effectively return people to health. The clinical guidelines and analytical tools within ODG are designed to improve and benchmark return-to-work performance, facilitate quality care while limiting inappropriate utilization, assess claim risk for interventional triage, and set reserves based on industry data.
About MCG
MCG, part of the Hearst Health network, provides unbiased clinical guidance that gives healthcare organizations confidence in delivering patient-centered care. MCG’s artificial intelligence and technology, infused with clinical expertise, enable its clients to prioritize and simplify their work. MCG’s world-class customer service ensures clients maximize the benefits of licensing MCG solutions – demonstrating improved clinical and financial outcomes. For more information visit http://www.mcg.com.
Media Contact
Arri Burgess, MCG Health, (206) 389-5405, [email protected], https://www.mcg.com/
SOURCE MCG Health
[ad_2]
[ad_1]
After 25 years in practice, new partner takes leadership opportunity in his hometown community.
MELVILLE, N.Y., Sept. 6, 2023 /PRNewswire-PRWeb/ — Professional Physical Therapy, the largest provider of certified Hand Therapy in the Northeast, announces they entered a strategic partnership with Evan Ludin, MS, OTR/L, CHT in their Hauppauge NY location. After nearly 25 years in practice and being with Professional for over seven years, Evan became part of Professional’s strategic partnership program that provides a unique affiliation solution to clinicians and leaders who are vested in ownership and operations. The collaboration represents a leadership opportunity for Evan and the ability to lead and further enhance the occupational therapist-patient experience.
The new Clinical Director Partner and Occupational Therapist, Evan Ludin, MS, OTR/L, CHT is excited to partner with Professional and adds “After 25 years in practice, I chose to redirect my patient care experience as a partner & clinical director in Hauppauge, my hometown community, with Professional PT. My passion for providing expert patient centered care in the private sector affords me the opportunity to provide upper extremity rehabilitation and splinting for patients. I draw upon the importance and understanding of radiographic healing and tissue equilibrium when considering all stages of rehabilitation. These principles guide my patient’s readiness for return to all aspects of life from basic self-care to competitive sports, work, and Activities of Daily Living (ADL’s).”
Evan completed his master’s degree in occupational therapy at Touro College. He has extensive experience working with patients of all ages. His specialty services include occupational therapy, custom splinting, and post-surgical rehabilitation of the elbow and hand.
Additionally, the Hauppauge clinic:
Professional Physical Therapy currently operates widely across five of the Northeast states. For more information and a list of all Professional Physical Therapy locations and hand therapy services, please visit http://www.professionalpt.com
About Professional Physical Therapy
Professional Physical Therapy was founded in 1999 and is an industry leader, providing private outpatient physical and hand therapy services throughout the Northeast. Our clinical team is comprised of multi-specialty Physical, Hand and Occupational Therapists who can treat a wide variety of orthopedic injuries and conditions with excellence. Today, Professional has grown to include over 190 facilities in New York, New Jersey, Connecticut, Massachusetts, and New Hampshire.
Media Contact
Professional Physical Therapy, Professional Physical Therapy, 516-321-2400, [email protected], https://www.professionalpt.com/
SOURCE Professional Physical Therapy
[ad_2]
[ad_1]
SHENZHEN, China, 5 de septiembre de 2023 /PRNewswire/ — SIBIONICS, líder en electrónica de consumo biométrica, se complace en anunciar el lanzamiento del sistema de monitoreo continuo de cetonas (CKM) SIBIO KS1, el dispositivo portátil biométrico más nuevo de la compañía diseñado para…
[ad_2]
